Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939415 · ClinicalTrials.gov registry record · Phase 1
RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
A Phase 1 study of Covid19, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04939415 is a Phase 1 study of Covid19 that has completed, run by University of California, San Diego. The registered enrollment target is 60 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04939415, a Phase 1 study of Covid19, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate a 21-herb formula named modified Qing Fei Pai Du Tang (mQFPD) to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. This the study aims to establish the safety and feasibility of the use of mQFPD vs placebo in 66 total subjects. Subsequent trials will evaluate other therapeutics as well as the efficacy of mQFPD in a larger study population.
Conditions Studied
Interventions
- DRUG mQFPD
- DRUG organic brown rice
Study Locations (2)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2022-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04939415
The ClinicalTrials.gov registry entry for NCT04939415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which mQFPD is the first listed.
NCT04939415 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04939415 about?
NCT04939415 is a clinical study titled "RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19". This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate a 21-herb formula named modified Qing Fei Pai Du Tang (mQFPD) to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. This the study aims to...
What is the current status of trial NCT04939415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-07-01. Estimated completion is 2022-03-13.
What conditions does trial NCT04939415 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04939415?
The interventions under investigation include: mQFPD (DRUG), organic brown rice (DRUG).
Who is sponsoring clinical trial NCT04939415?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04939415 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MRI of Survivors of COVID-19
ACTIVE NOT RECRUITING · Phase 1
-
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
COMPLETED · Phase 1
-
Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection
COMPLETED · Phase 1
-
COVID-19 Study of Safety and Tolerability of Alvelestat
COMPLETED · Phase 1
-
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
COMPLETED · Phase 1
-
Electrical Stimulation for Critically Ill Covid-19 Patients
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.